Skye Bioscience (SKYE) Earnings Analysis
Skye Bioscience (SKYE) next reports earnings on 2026-08-06, consensus EPS -0.29 USD. Last quarter (2026-05-11) it missed with EPS -0.32 USD vs -0.29 USD est (-10.3%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -0.44.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SKYE next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.29 USD |
| Revenue estimate | n/a |
SKYE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.32 USD | -0.29 USD | -10.3% | Miss |
| 2026-03-10 | -0.36 USD | -0.2971 USD | -21.2% | Miss |
| 2025-11-10 | -0.32 USD | -0.33 USD | +3% | Beat |
| 2025-05-08 | -0.28 USD | -0.31 USD | +9.7% | Beat |
| 2025-03-20 | -0.24 USD | -0.28 USD | +14.3% | Beat |
| 2024-08-09 | -0.2 USD | -0.2 USD | 0% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
SKYE valuation and analyst view
| Trailing P/E | -0.44 |
|---|---|
| Trailing EPS | -1.44478 USD |
| Price / book | 2.82 |
| Dividend yield | 0.00% |
| Market cap | 0.02B |
| Analyst consensus | Buy (5 buy / 0 hold / 0 sell) |
| Avg price target | 2 USD |
Related research pages
Frequently asked questions
When is Skye Bioscience (SKYE)'s next earnings date?
Skye Bioscience is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.29 USD.
Did SKYE beat earnings last quarter?
In its 2026-05-11 report, SKYE posted EPS of -0.32 USD versus a -0.29 USD estimate — a miss of 10.3%.
What is SKYE's earnings track record?
Over the last 6 reported quarters with consensus data, SKYE beat estimates 4 times (67%).
What is SKYE's current P/E ratio and EPS?
SKYE trades at a trailing P/E of -0.44 on trailing EPS of -1.4447766986425525 USD.
What do analysts rate SKYE?
Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 2 USD.